Trial
NCT01887912
Study of a Candidate Clostridium Difficile Toxoid Vaccine in Subjects at Risk for C. Difficile Infection
Phase IIITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Sanofi Pasteur, a Sanofi Company
Collaborators
—
Condition
Clostridium Difficile Infection
Intervention
C. difficile Toxoid Vaccine
Why stopped
The Independent Data Monitoring Committee (IDMC) concluded that the probability that the study will meet its primary objective is low.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-03-28